Exparel: Phase III data

Data from 183 patients undergoing total knee arthroplasty in the Phase III portion of a 2-part, double-blind, U.S. Phase II/III trial showed that a single femoral nerve blocking administration of 266 mg Exparel met the primary endpoint of reducing cumulative pain intensity scores through 72 hours vs. placebo (p<0.0001). Pacira said that the preliminary safety analysis was comparable between the groups. Patients were offered rescue narcotics as needed. The first part of the trial evaluated a single injection of 67, 133 and 266 mg Exparel in about 100 patients (see BioCentury, June 10, 2013). ...